-
2023-510191-31-00
Benign Prostate Hyperplasia 5
-
2024-519922-19-00
Neuroendocrine carcinoma of gastro-enteropancreatic or 4
-
2025-523913-27-00
Participants with R0/R1 resected liver metastases from 5
-
2025-524408-30-01
Metastatic hormone-sensitive prostate cancer 5 2026-06-05
-
2022-502425-18-00
Adenocarcinoma of the prostate 5 2022-04-19
-
2025-522108-26-00
métastatique colorectal cancer 4 2026-02-19
-
2025-522395-92-00
metastatic oeso-gastric adenocarcinoma 5 2025-12-15
-
2024-519493-39-00
High-risk Non-muscle-invasive Bladder
Cancer with Susce 5 2025-12-09
-
2024-519654-37-00
Recurrent or Metastatic Head and Neck Squamous Cell Car 10 2025-11-07
-
2024-514030-20-00
colorectal cancer 4 2025-08-29
-
2024-515349-41-00
Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
-
2024-510893-25-00
Brain metastases of cancer > brain radionecrosis 5 2025-04-29
-
2024-510772-20-00
Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
-
2024-511652-40-00
METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
-
2023-504554-35-00
incisional hernia 5 2025-01-17
-
2024-511070-68-01
Ampullary adenocarcinoma 5 2024-09-24
-
2024-515297-27-00
colon carcinoma 5 2024-08-14
-
2024-515788-73-00
MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
-
2023-505214-23-00
colon carcinoma 5 2024-06-07
-
2023-504323-25-01
breast cancer 5 2024-03-19
-
2023-506891-28-00
The target population of interest in this study is part 5 2022-05-02
-
2024-511904-18-00
Pancreatic adenocarcinoma (PAC) 10 2020-07-08
-
2023-508302-24-00
Locally Advanced/Metastatic Urothelial Cancer 4 2019-05-07
-
2023-506146-23-00
Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the 4 2025-11-17